intravenous iclaprim or intravenous linezolid — Competitive Intelligence Brief

intravenous iclaprim or intravenous linezolid (intravenous iclaprim or intravenous linezolid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxazolidinone antibiotic. Area: Infectious disease.

phase 3 Oxazolidinone antibiotic 50S ribosomal subunit Infectious disease Small molecule

Target snapshot

intravenous iclaprim or intravenous linezolid (intravenous iclaprim or intravenous linezolid) — Arpida AG. Iclaprim inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intravenous iclaprim or intravenous linezolid TARGET	intravenous iclaprim or intravenous linezolid	Arpida AG	phase 3	Oxazolidinone antibiotic	50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Azithromycin 1 gram IV	Azithromycin 1 gram IV	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Linezolid Injectable Product	Linezolid Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
PRISTINAMYCIN XRP7263	PRISTINAMYCIN XRP7263	Sanofi	marketed	Macrolide antibiotic / Streptogramin	Bacterial 50S ribosomal subunit
Linezolid (LZD)	Linezolid (LZD)	Wuhan Pulmonary Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Azithromycin or placebo tablets	Azithromycin or placebo tablets	Rigshospitalet, Denmark	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxazolidinone antibiotic class)

1. Fundacion Clinic per a la Recerca Biomédica · 2 drugs in this class
2. University of Southern California · 2 drugs in this class
3. Arpida AG · 2 drugs in this class
4. Pfizer · 1 drug in this class
5. Shenzhen Third People's Hospital · 1 drug in this class
6. Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
7. Wuhan Pulmonary Hospital · 1 drug in this class
8. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class